JP2012521768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012521768A5 JP2012521768A5 JP2012502294A JP2012502294A JP2012521768A5 JP 2012521768 A5 JP2012521768 A5 JP 2012521768A5 JP 2012502294 A JP2012502294 A JP 2012502294A JP 2012502294 A JP2012502294 A JP 2012502294A JP 2012521768 A5 JP2012521768 A5 JP 2012521768A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding protein
- bispecific binding
- cancer
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000023732 binding proteins Human genes 0.000 claims 17
- 108091008324 binding proteins Proteins 0.000 claims 17
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 9
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 9
- 108091008794 FGF receptors Proteins 0.000 claims 7
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims 7
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 5
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims 3
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 206010073363 Acinar cell carcinoma of pancreas Diseases 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000024558 digestive system cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000010287 pancreatic acinar cell adenocarcinoma Diseases 0.000 claims 1
- 208000030352 pancreatic acinar cell carcinoma Diseases 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16402309P | 2009-03-27 | 2009-03-27 | |
| US61/164,023 | 2009-03-27 | ||
| PCT/US2010/028877 WO2010111625A1 (en) | 2009-03-27 | 2010-03-26 | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012521768A JP2012521768A (ja) | 2012-09-20 |
| JP2012521768A5 true JP2012521768A5 (cg-RX-API-DMAC7.html) | 2013-05-09 |
Family
ID=42332479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012502294A Pending JP2012521768A (ja) | 2009-03-27 | 2010-03-26 | 抗体−受容体の組み合わせを含む多特異的結合性タンパク質を用いるための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120134993A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2411407A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012521768A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20110134494A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102448984A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010229705A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011009810A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010111625A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
| US9726677B2 (en) * | 2013-03-15 | 2017-08-08 | Intermune, Inc. | Proteomic IPF markers |
| US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
| US9920096B2 (en) | 2013-06-25 | 2018-03-20 | Sepia Pesquisa E Desenvolvimento | Bradykinin receptor modulators and use thereof |
| KR102060187B1 (ko) | 2013-07-19 | 2019-12-27 | 삼성전자주식회사 | Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도 |
| WO2015035342A2 (en) | 2013-09-08 | 2015-03-12 | Oligasis Llc | Factor viii zwitterionic polymer conjugates |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CN107428824A (zh) * | 2014-06-28 | 2017-12-01 | 科达制药 | Pdgf/vegf双重拮抗剂 |
| CN104177492B (zh) * | 2014-07-21 | 2017-02-22 | 暨南大学 | FGFR2c胞外段类似物及其编码基因与应用 |
| HUE058219T2 (hu) | 2014-09-26 | 2022-07-28 | Janssen Pharmaceutica Nv | FGFR-mutánsgénpanel alkalmazása olyan rákbetegek azonosításában, akik FGFR-inhibitorral történõ kezelésre reszponzívak lesznek |
| WO2016061562A2 (en) | 2014-10-17 | 2016-04-21 | Kodiak Sciences Inc. | Butyrylcholinesterase zwitterionic polymer conjugates |
| IL305193A (en) | 2014-12-22 | 2023-10-01 | Systimmune Inc | Bispecific tetravalent antibodies and methods for their preparation and use |
| US12428483B2 (en) | 2014-12-22 | 2025-09-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| BR112018000696A2 (pt) | 2015-07-15 | 2018-09-18 | Genmab As | ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit? |
| EA035586B1 (ru) * | 2015-11-30 | 2020-07-10 | Пиерис Острелиа Пти Лтд. | Новые антиангиогенные слитые белки |
| JP7088454B2 (ja) | 2015-12-30 | 2022-06-21 | コディアック サイエンシーズ インコーポレイテッド | 抗体および抗体複合体 |
| MA45672A (fr) | 2016-07-14 | 2019-05-22 | Biontech Ag | Anticorps multispécifiques dirigés contre cd40 et cd137 |
| LT3592769T (lt) | 2017-03-09 | 2024-08-26 | Genmab A/S | Antikūnai, atpažįstantys pd-l1 |
| WO2018178396A1 (en) | 2017-03-31 | 2018-10-04 | Genmab Holding B.V. | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof |
| CN111406067B (zh) | 2017-08-04 | 2022-11-08 | 健玛保 | 与pd-l1和cd137结合的结合剂及其用途 |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| CA3113409A1 (en) | 2018-09-19 | 2020-03-26 | Lava Therapeutics B.V. | Dual acting cd1d immunoglobulin |
| WO2020070313A1 (en) | 2018-10-04 | 2020-04-09 | Genmab Holding B.V. | Pharmaceutical compositions comprising bispecific anti-cd37 antibodies |
| WO2020094744A1 (en) | 2018-11-06 | 2020-05-14 | Genmab A/S | Antibody formulation |
| NL2022494B1 (en) | 2019-02-01 | 2020-08-19 | Lava Therapeutics B V | Novel CD40-binding antibodies |
| WO2020159368A1 (en) | 2019-02-01 | 2020-08-06 | Lava Therapeutics B.V. | Novel cd40-binding antibodies |
| US20220267452A1 (en) * | 2019-07-12 | 2022-08-25 | Chugai Seiyaku Kabushiki Kaisha | Anti-mutation type fgfr3 antibody and use therefor |
| EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
| CN115298221A (zh) | 2020-03-18 | 2022-11-04 | 健玛保 | 结合b7h4的抗体 |
| CN115916166A (zh) | 2020-05-08 | 2023-04-04 | 健玛保 | 针对cd3和cd20的双特异性抗体 |
| CA3188601A1 (en) | 2020-07-08 | 2022-01-13 | LAVA Therapeutics N.V. | Antibodies that bind psma and gamma-delta t cell receptors |
| AU2021322046A1 (en) | 2020-08-06 | 2023-02-02 | BioNTech SE | Binding agents for coronavirus S protein |
| CA3190349A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia |
| CA3192251A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| IL303045A (en) | 2020-12-10 | 2023-07-01 | Lava Therapeutics N V | Antibodies that bind gamma-delta t cell receptors |
| WO2022180271A1 (en) | 2021-02-26 | 2022-09-01 | LAVA Therapeutics N.V. | Antibodies that bind CD123 and gamma-delta T cell receptors |
| MX2023012351A (es) | 2021-05-07 | 2023-10-31 | Genmab As | Composiciones farmaceuticas que comprenden anticuerpos biespecificos que se unen al inhibidor de la activacion de celulas t que contiene un dominio v-set 1 (b7h4) y cumulo de diferenciacion 3 (cd3). |
| IL309319A (en) | 2021-06-21 | 2024-02-01 | Genmab As | Combined dosage regimen CD137 and PD-L1 binding agents |
| TW202328193A (zh) | 2021-09-13 | 2023-07-16 | 美商健生生物科技公司 | 用於治療癌症的CD33 x Vδ2多特異性抗體 |
| IL311805A (en) | 2021-10-08 | 2024-05-01 | Genmab As | Antibodies that bind to CD30 and CD3 |
| EP4419109A1 (en) | 2021-10-21 | 2024-08-28 | LAVA Therapeutics N.V. | Uses of gamma delta t cell activating antibodies |
| WO2023174521A1 (en) | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
| EP4285926A1 (en) | 2022-05-30 | 2023-12-06 | LAVA Therapeutics N.V. | Combination treatment for chronic lymphocytic leukemia |
| EP4292609A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
| EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| NL2032398B1 (en) | 2022-07-06 | 2024-01-23 | Academisch Ziekenhuis Leiden | Bispecific antibody and uses thereof |
| CN118420715B (zh) * | 2023-03-23 | 2025-01-24 | 湖南中晟全肽生物科技股份有限公司 | 一种结合fgfr2受体的多肽及其用途 |
| WO2024200573A1 (en) | 2023-03-27 | 2024-10-03 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| EP4438624A1 (en) | 2023-03-27 | 2024-10-02 | LAVA Therapeutics N.V. | Antibodies that bind nectin-4 and gamma-delta t cell receptors |
| TW202506178A (zh) | 2023-04-05 | 2025-02-16 | 丹麥商珍美寶股份有限公司 | 包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物 |
| JP2025530208A (ja) | 2023-06-30 | 2025-09-11 | ジェンマブ エー／エス | 線維芽細胞活性化タンパク質アルファおよびデスレセプター４に結合する抗体 |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| WO2025024780A1 (en) | 2023-07-27 | 2025-01-30 | LAVA Therapeutics N.V. | Antibodies that bind gamma-delta t cell receptors for the treatment of cancer |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002083704A1 (en) * | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| AU2002339863A1 (en) * | 2001-08-31 | 2003-03-18 | Abmaxis, Inc. | Multivalent protein conjugate with multiple ligand-binding domains of receptors |
| WO2005087812A1 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
| CN1997382A (zh) * | 2004-05-05 | 2007-07-11 | 梅里麦克制药股份有限公司 | 调节生物活性的双特异性结合剂 |
| CA2614039C (en) * | 2005-07-22 | 2015-10-13 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| EP2190861A4 (en) * | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| EP2604279A1 (en) * | 2008-03-27 | 2013-06-19 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
-
2010
- 2010-03-26 WO PCT/US2010/028877 patent/WO2010111625A1/en not_active Ceased
- 2010-03-26 AU AU2010229705A patent/AU2010229705A1/en not_active Abandoned
- 2010-03-26 JP JP2012502294A patent/JP2012521768A/ja active Pending
- 2010-03-26 EP EP10722828A patent/EP2411407A1/en not_active Ceased
- 2010-03-26 US US13/260,408 patent/US20120134993A1/en not_active Abandoned
- 2010-03-26 CN CN2010800230893A patent/CN102448984A/zh active Pending
- 2010-03-26 KR KR1020117025299A patent/KR20110134494A/ko not_active Ceased
- 2010-03-26 MX MX2011009810A patent/MX2011009810A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012521768A5 (cg-RX-API-DMAC7.html) | ||
| JP2009505676A5 (cg-RX-API-DMAC7.html) | ||
| Lafitte et al. | Roles of exosomes in metastatic colorectal cancer | |
| NZ594479A (en) | Diagnosis and treatment of gastric-type cancers with siRNA, modified antibodies, or immunotherapy approaches | |
| Wang et al. | Breast cancer stem cells: signaling pathways, cellular interactions, and therapeutic implications | |
| UA114108C2 (uk) | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання | |
| ME02692B (me) | NOVA IMUNOTERAPIJA PROTIV NEKOLIKO TUMORA UKLJUČUJUĆI GASTROINTESTINALNI KARCINOM l KARCINOM ŽELUCA | |
| WO2012097313A3 (en) | Therapeutic antibodies against ror-1 protein and methods for use of same | |
| RU2013104830A (ru) | Лечение рака при помощи направленных на мишень антител in vivo | |
| JP2012100677A5 (cg-RX-API-DMAC7.html) | ||
| PH12013500410B1 (en) | Vegf-binding molecules | |
| JP2019536426A5 (cg-RX-API-DMAC7.html) | ||
| JP2013166763A5 (cg-RX-API-DMAC7.html) | ||
| NZ588587A (en) | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma | |
| TN2009000194A1 (en) | Novel antiproliferation antibodies | |
| Singh et al. | Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cells | |
| RU2012143943A (ru) | КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ МЕТАСТАЗОВ РАКА, СОДЕРЖАЩАЯ СЛИТЫЙ БЕЛОК DLK1-Fc В КАЧЕСТВЕ ЭФФЕКТИВНОГО ИНГРЕДИЕНТА | |
| WO2011116212A3 (en) | Bone morphogenetic protein receptor binding agents and methods of their use | |
| JP2013511559A5 (cg-RX-API-DMAC7.html) | ||
| You et al. | COMMD7 promotes hepatocellular carcinoma through regulating CXCL10 | |
| JP2020516668A5 (cg-RX-API-DMAC7.html) | ||
| JP2014510699A5 (cg-RX-API-DMAC7.html) | ||
| Liang et al. | Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers | |
| WO2009124281A3 (en) | Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis | |
| Wei et al. | Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment |